James Frederick is a practicing Physician Associate (PA-C, MMSc) who studied at Yale University. He also has a bachelor’s degree in creative writing and English Literature from the University of Colorado. He specializes in writing medical content that is approachable, readable and enjoyable. He has a strong background in research, physiology, pharmacotherapy, emergency medicine and critical care medicine. In his free time, he enjoys spending time camping and traveling with his wife and dog.
People with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL) who were treated with Imbruvica (ibrutinib) in a clinical trial — and then followed for several years — ... Read more
Recently announced data from a Phase 1 trial for investigational T-cell therapy JCAR017 shows a high response rate for patients with relapsed or refractory CD19+ aggressive B-cell non-Hodgkin lymphoma (NHL), ... Read more
The immune checkpoint inhibitor Opdivo (nivolumab) may induce remission in classical Hodgkin lymphoma (cHL) patients who have relapsed following an allogeneic hematopoietic stem cell transplant. That was the conclusion of a new ... Read more